Upadacitinib + Placebo

Phase 3Recruiting

0 views this week 0 watching⚡ Active

Interest: 47/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Hidradenitis Suppurativa

Conditions

Hidradenitis Suppurativa

Trial Timeline

Jun 21, 2023 → Mar 1, 2028

NCT ID

NCT05889182

About Upadacitinib + Placebo

Upadacitinib + Placebo is a phase 3 stage product being developed by AbbVie for Hidradenitis Suppurativa. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05889182. Target conditions include Hidradenitis Suppurativa.

What happened to similar drugs?

1 of 20 similar drugs in Hidradenitis Suppurativa were approved

Approved (1) Terminated (0) Active (19)

✅Placebo + AdalimumabAbbVieApproved

🔄SonelokimabMoonLake ImmunotherapeuticsPhase 3

🔄Sonelokimab + PlaceboMoonLake ImmunotherapeuticsPhase 3

🔄Lutikizumab + PlaceboAbbViePhase 3

🔄adalimumab + placeboAbbViePhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (10)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06118411	Phase 3	Active	Dec 19, 2023	Feb 1, 2028	Vitiligo
NCT06012240	Phase 3	Recruiting	Oct 11, 2023	Jan 1, 2028	Alopecia Areata
NCT05843643	Phase 3	Recruiting	Jul 19, 2023	Oct 1, 2027	Systemic Lupus Erythematosus
NCT05889182	Phase 3	Recruiting	Jun 21, 2023	Mar 1, 2028	Hidradenitis Suppurativa
NCT04927975	Phase 2	Completed	Jun 30, 2021	Aug 29, 2023	Non-Segmental Vitiligo
NCT04430855	Phase 2	Completed	Jul 14, 2020	Jan 25, 2022	Hidradenitis Suppurativa (HS)
NCT04169373	Phase 3	Completed	Nov 26, 2019	Feb 28, 2025	Spondyloarthritis
NCT02955212	Phase 3	Completed	Jan 3, 2018	Sep 3, 2020	Rheumatoid Arthritis (RA)
NCT03178487	Phase 2	Completed	Oct 24, 2017	Feb 17, 2022	Ankylosing Spondylitis (AS)
NCT02925117	Phase 2	Completed	Oct 25, 2016	Jan 31, 2019	Atopic Dermatitis

Competing Products

20 competing products in Hidradenitis Suppurativa

See all competitors

Product	Company	Stage	Hype Score
Sonelokimab	MoonLake Immunotherapeutics	Phase 3	41
Sonelokimab	MoonLake Immunotherapeutics	Phase 3	41
Sonelokimab + Placebo	MoonLake Immunotherapeutics	Phase 3	38
Sonelokimab + Placebo	MoonLake Immunotherapeutics	Phase 3	38
Sonelokimab (M1095) + Adalimumab	MoonLake Immunotherapeutics	Phase 2	29
Eltrekibart + Placebo	Eli Lilly	Phase 2	39
Placebo + LY3041658	Eli Lilly	Phase 2	35
Placebo + Adalimumab	AbbVie	Approved	43
Lutikizumab + Placebo	AbbVie	Phase 3	47
Adalimumab	AbbVie	Pre-clinical	26
adalimumab + placebo	AbbVie	Phase 3	40
Lutikizumab	AbbVie	Phase 2	42
adalimumab	AbbVie	Phase 3	40
Lutikizumab + Placebo	AbbVie	Phase 2	39
Risankizumab + Placebo for risankizumab	AbbVie	Phase 2	35
adalimumab	AbbVie	Phase 3	40
adalimumab + placebo	AbbVie	Phase 3	40
Upadacitinib + Placebo	AbbVie	Phase 2	35
MEDI8968 + Saline	AstraZeneca	Phase 2	27
Anifrolumab	AstraZeneca	Phase 2	39